The treatment of congenital bleeding disorders is rapidly evolving with the approval of multiple new products for the treatment of hemophilia A, hemophilia B, and the rare bleeding disorders. In addition there are also multiple new classes of products in the development pipeline. This session will focus on these recent advances in treatment.
Dr. Steven Pipe will discuss new therapies for hemophilia including how the introduction of extended half-life products has changed the management of patients.
Dr. Shannon Meeks will review the current management options for hemophilia patients with inhibitors. She will also address novel therapies that are currently in clinical trials.
Dr. Flora Peyvandi will present the current state of therapeutics in rare bleeding disorders.